Article

AMO's board of directors names Mazzo as chairman

Advanced Medical Optics (AMO) Inc.'s board of directors elected its director, president, and chief executive officer (CEO) James V. Mazzo to also be chairman of the board. Mazzo succeeds William R. Grant, who served as the company's chairman since its spin-off from Allergan Inc. in 2002. Grant remains a member of AMO's board.

Advanced Medical Optics (AMO) Inc.'s Board of Directors elected its Director, President, and Chief Executive Officer (CEO) James V. Mazzo to also be chairman of the board. Mazzo succeeds William R. Grant, who served as the company's chairman since its spin-off from Allergan Inc. in 2002. Grant remains a member of AMO's board.

"I believe this is an ideal time for me to step aside and transition the chairmanship to Jim Mazzo," said Grant. "I am confident in his ability to guide the board and AMO to an even brighter future."

Since Mazzo became president and CEO in 2002, AMO has nearly doubled its annual revenue to about $1 billion and improved its earnings power through a series of strategic acquisitions and growth initiatives, according to the company.

"On behalf of the board of directors, management team, and 3,500 employees across the globe, I want to thank Bill Grant for his leadership during these first critical years of our company's independence," said Mazzo. "His experience, wisdom, and professionalism have been invaluable to me and everyone else associated with the AMO organization."

The AMO board announced that the independent directors named James O. Rollans as presiding director. He will routinely preside over executive sessions and board meetings when the chairman is not present. Rollans has served as an AMO director and chairman of its Audit and Finance Committee since 2002.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.